Blocking a Specific Part of ACE Prevents the Brain from Breaking Down Natural Opioid Peptides

Using brain slices from mutant mice with functional inactivation of either ACE catalytic domain, researchers demonstrated that only N-terminal domain inactivation reduced the degradation of Met-enkephalin-Arg-Phe (MERF) to Met-enkephalin. C-terminal domain inactivation had no effect. A selective N-terminal domain inhibitor (RXP 407) reduced degradation of both exogenously applied and endogenously released MERF, while leaving degradation of Met-enkephalin and Leu-enkephalin unaffected.

Researchers used acute brain slice preparations from mice of both sexes, including mutant lines with functional inactivation of either the N-terminal or C-terminal ACE domain. Brain slices were incubated with exogenous MERF at saturating concentration and degradation was measured. A selective N-terminal domain inhibitor (RXP 407) was also tested on degradation of both exogenously applied and endogenously released enkephalin peptides.

Current opioid medications work by flooding receptors with synthetic agonists, causing tolerance and addiction. Boosting the brain's own opioid peptides by preventing their breakdown could be safer. This study identifies a precise molecular target — the ACE N-terminal domain — that could enable this strategy.

This research sits at the intersection of two well-studied peptide systems: the angiotensin system (blood pressure) and the endogenous opioid system (pain and mood). By showing that a specific domain of ACE selectively degrades a specific opioid peptide in the brain, it opens a highly targeted pharmacological approach. Rather than the blunt instrument of opioid agonists, future drugs could fine-tune the brain's own opioid tone by modulating peptide degradation.

Preprint not yet peer-reviewed. Ex vivo brain slice study, not in vivo. No behavioral outcomes measured. Translation to human brain physiology unknown. Selective inhibitor tested only in tissue, not in living animals.